spacer
home > pmps > winter 2001 > an introduction to transdermal drug delivery systems
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

An Introduction to Transdermal Drug Delivery Systems

In the first part of this article in the Autumn 2001 issue of PMPS, we analysed the varieties, the structure and the basic components of patches. This 'promenade' was important in order to better understand how these drug delivery systems are composed. In this second part we will follow the processes involved in the production of the two major classes, matrix and liquid reservoir patches. We will then finish with a detailed description of the whole production chain for the most popular class at present - the matrix systems.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Spyridon A. Fotinos, Executive Vice President - Corporate Research & Innovation, at Lavipharm Group of Companies
Spyridon Fotinos studied pharmaceutics at the University of Athens, before going on to study chemistry at the University of Thessaloniki. He joined Lavipharm in 1979, and in 1987, established the Research and Development Department, of which he has since become a Director.
Spyridon's current position is Executive Vice President - Corporate Research and Innovation. Prior to his time at Lavipharm, he served for four years as Director of Planning and Studies at Minerva Pharmaceuticals. Spyridon is a patent holder in the areas of pharmaceutical and cosmetic delivery technology, antioxidant and enzymic systems. He is also a member of several Greek and international scientific organisations.

spacer
Spyridon A. Fotinos
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

3P Biopharmaceuticals enters into manufacturing agreement with the Swedish company Affibody

[Noáin, May 27, 2019] 3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics, has signed a collaboration agreement with the Swedish company Affibody for the process transfer, scale-up and GMP commercial manufacturing of a recombinant protein sole property of Affibody.
More info >>

White Papers

Delivering Fit For Purpose Biomanufacturing CHO Cell Lines

Fujifilm Diosynth Biotechnologies

The challenge during mammalian cell line development is to identify and isolate stable, high expressing cell lines producing product with the appropriate critical product quality attributes rapidly, reproducibly and with relative ease. Obtaining a host cell line that inherently exhibits desirable biomanufacturing attributes can therefore have a significantly positive effect on the identification of recombinant cell lines with desired traits during cell line development screens. In this study, we demonstrate that it is possible to exploit intrinsic heterogeneity within host cell populations and identify host cell lines which are more “fit for purpose”.
More info >>

 
Industry Events

SAPHEX 2019

23-24 October 2019, GALLAGHER CONVENTION CENTRE, 10 RICHARDS DRIVE, HALFWAY HOUSE, MIDRAND, 1685, SOUTH AFRICA

SAPHEX 2019 will be held on the 23rd-24th October at the Gallagher Convention Centre, Johannesburg, South Africa.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement